Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis

  • Laura Dumont Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • Adriano Salaroli Department of Hematology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • Lissandra Dal Lago Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • Thierry Gil Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • Thierry Pepersack Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Keywords

Prostate cancer, reactive hemophagocytic lymphohistiocytosis, hyperferritinemia, Drug-induced-pancytopenia, hypertriglyceridemia, HScore

Abstract

We report the case of a 76-year-old man presenting with reactive haemophagocytic lymphohistiocytosis (rHLH) in the setting of disseminated prostate cancer. This often fatal syndrome must be diagnosed early in order to maximize survival. Treatment should be initiated whenever the clinical diagnosis is suspected, even if the HLH-2004 criteria are not met. The HScore is a useful diagnostic tool for rHLH. In case of neurological symptoms, an extensive assessment must be performed. The goal of this case report is to raise awareness of this rare syndrome among oncologists.

VIEW THE ENTIRE ARTICLE

References

  • Koizumi K, Haseyama Y, Machino R, Sato Y, Sawada K, Koike T. The hemophagocytic syndrome in prostate cancer revealed by disseminated carcinomatosis of the bone marrow. J Urol 2002;168(3):1101–1102.
  • Declerck L, Adenis C, Amela E, Caty A, Adenis A, Penel N. Prostate cancer related haemophagocytic syndrome: successful treatment with chemotherapy. Acta Oncol 2012;51(2):268–269.
  • Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 2017;130(25):2728–2738.
  • Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome: score for reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66(9):2613–2620.
  • Vaidya HC, Wolf BA, Garrett N, Catalona WJ, Clayman RV, Nahm MH. Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the ‘hook effect’. Clin Chem 1988;34(10):2175–2177.
  • Novotny F, Simonetta F, Samii K, Chalandon Y, Serratrice J. Syndrome hémophagocytaire réactionnel. Rev Med Suisse 2017;13:1797–1803. Available from: https://www.revmed.ch/RMS/2017/RMS-N-579/Syndrome-hemophagocytaire-reactionnel#B28.
  • Published: 2021-04-01

    Issue: LATEST ONLINE (view)

    Section: Articles

    How to cite:
    1.
    Dumont L, Salaroli A, Dal Lago L, Gil T, Pepersack T. Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis. EJCRIM 2021;2 doi:10.12890/2021_002425.

    Most read articles by the same author(s)